Bacterial resistance to antimicrobial agents is a significant threat to the efficacy of antibiotic therapy. The ?-lactam antibiotics, such as the penicillins and cephalosporins, are among the most often used antimicrobials. The most common source of resistance to ?-lactam antibiotics is the production of ?-lactamases, which cleave the drugs and render them ineffective. ?-lactamases have been grouped into four classes based on primary sequence homology. Classes A, C and D are active-site serine enzymes that catalyze the hydrolysis of ?-lactam antibiotics via a serine-bound acyl-enzyme intermediate. Class B enzymes require zinc for activity and catalysis does not proceed via a covalent intermediate. Because of the wide range of substrate specificities of these enzymes, virtually all ?-lactam antibiotics are susceptible to hydrolysis. Clearly, the design of new antibiotics that escape hydrolysis by the growing collection of ?-lactamase activities will be a challenge. It will be necessary to understand the catalytic mechanism and basis for substrate specificity of each class of ?-lactamase. The goal of this work is to understand how the amino acid sequence determines the structure, activity and evolution of class A ?-lactamases. The TEM-1 and CTX-M family of class A enzymes are an important cause of resistance to ?-lactam antibiotics worldwide. In a previous funding period in vitro mutagenesis was used to randomize the entire coding sequence of the class A TEM-1 ?-lactamase. The sets of random mutants were used to identify residues that are critical for the folding, stability and substrate specificity of the enzyme. The recent advent and application of ultra-high throughput sequencing technology has allowed the scope of this approach to be vastly extended to accurately determine the sequence requirements for hydrolysis of multiple classes of ?-lactam antibiotics for every residue position in TEM-1 ?-lactamase. In addition, preliminary studies suggest that amino acid substitutions which increase the stability of TEM-1 ?-lactamase play an important role in the evolution of TEM-1-mediated resistance to extended-spectrum ?-lactam antibiotics and ?-lactamase inhibitors. These studies will be continued to understand how these changes influence the stability and activity of evolved enzyme variants. Finally, the CTX-M family of ?-lactamases exhibits a high degree of sequence variation and it is hypothesized that many of the amino acid substitutions observed alter the stability or substrate specificity of the enzymes. Experiments are proposed to test this hypothesis by examining the role of a selected set of amino acid substitutions on the structure, activity and evolution of CTX-M enzymes.

Public Health Relevance

This project addresses how bacterial resistance to ?-lactam antibiotics such as the penicillins and cephalosporins evolves. ?-lactamases catalyze the destruction of ?-lactam antibiotics and are the most common mechanism of resistance to these drugs. The proposed experiments will determine how amino acid substitutions in the sequence of ?-lactamase enzymes alter their structure, function and evolution, which will facilitate the design of new antimicrobial therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI032956-21
Application #
8240983
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Huntley, Clayton C
Project Start
1992-07-01
Project End
2016-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
21
Fiscal Year
2012
Total Cost
$387,578
Indirect Cost
$137,578
Name
Baylor College of Medicine
Department
Pharmacology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Long, S Wesley; Olsen, Randall J; Mehta, Shrenik C et al. (2014) PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 58:6668-74
Fryszczyn, Bartlomiej G; Adamski, Carolyn J; Brown, Nicholas G et al. (2014) Role of ?-lactamase residues in a common interface for binding the structurally unrelated inhibitory proteins BLIP and BLIP-II. Protein Sci 23:1235-46
Brown, Nicholas G; Chow, Dar-Chone; Ruprecht, Kevin E et al. (2013) Identification of the *-lactamase inhibitor protein-II (BLIP-II) interface residues essential for binding affinity and specificity for class A *-lactamases. J Biol Chem 288:17156-66
Brown, Nicholas G; Chow, Dar-Chone; Palzkill, Timothy (2013) BLIP-II is a highly potent inhibitor of Klebsiella pneumoniae carbapenemase (KPC-2). Antimicrob Agents Chemother 57:3398-401
Palzkill, Timothy (2013) Metallo-ýý-lactamase structure and function. Ann N Y Acad Sci 1277:91-104
Yuan, Ji; Chow, Dar-Chone; Huang, Wanzhi et al. (2011) Identification of a ýý-lactamase inhibitory protein variant that is a potent inhibitor of Staphylococcus PC1 ýý-lactamase. J Mol Biol 406:730-44
Kim, Jeong Joo; Casteel, Darren E; Huang, Gilbert et al. (2011) Co-crystal structures of PKG I? (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding. PLoS One 6:e18413
Brown, Nicholas G; Horton, Lori B; Huang, Wanzhi et al. (2011) Analysis of the functional contributions of Asn233 in metallo-?-lactamase IMP-1. Antimicrob Agents Chemother 55:5696-702
Fryszczyn, Bartlomiej G; Brown, Nicholas G; Huang, Wanzhi et al. (2011) Use of periplasmic target protein capture for phage display engineering of tight-binding protein-protein interactions. Protein Eng Des Sel 24:819-28
Brown, Nicholas G; Chow, Dar-Chone; Sankaran, Banumathi et al. (2011) Analysis of the binding forces driving the tight interactions between beta-lactamase inhibitory protein-II (BLIP-II) and class A beta-lactamases. J Biol Chem 286:32723-35

Showing the most recent 10 out of 51 publications